This is all IMO
Financial planning advice is all to do with how they are licenced.
The licence holder will have an approved list of investments (coys) that the licencees can recommend to clients.
Depending on the licence holder they may use a research house who has performed research on various companies
If large enough the licence holder may do their own research.
An alternate is a simple definition of being a ASX300 company
It is important to know each licencee has a different list of approved investments
However defined, the approved list of investments is covered in their PI insurance policy
Essentially any recommendation outside of the approved list would not be covered by Insurance and so the advisor is at risk.
(This is why financial planners do not recommend property because each property would have unique research which is costly)
As far as I know there are about 6 or 7 truly independent financial planning companies in Australia that can holistically look at your entire portfolio (including property) and provide advice.
Essentially it would be vary rare for any financial adviser to know about ADN.
It is a penny stock and considered very high risk.
What's my experience?
I use a financial planner who is licenced with a large Australian company (60 odd offices across Oz).
However, they do their own research at their office level.
They review in the order of 300 companies around the globe and only recommend about 43 of them for investing. (Blue Chip)
Essentially the office I use only recommends a subset of the licencees approved list
I do have an SMSF. My planner manages this, however, I have bought some ADN in it
Each time I have to advise them this investment decision is mine and they are not responsible.
I hope that may help some peeps
All IMO and not advice
GLTAH
- Forums
- ASX - By Stock
- ADN
- General comments/chat
General comments/chat, page-2464
-
- There are more pages in this discussion • 41,891 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ADN (ASX) to my watchlist
|
|||||
Last
1.7¢ |
Change
-0.001(2.94%) |
Mkt cap ! $51.31M |
Open | High | Low | Value | Volume |
1.6¢ | 1.7¢ | 1.6¢ | $16.47K | 988.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 3195456 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 2227714 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 3195456 | 0.016 |
28 | 9076447 | 0.015 |
19 | 5983035 | 0.014 |
6 | 1916592 | 0.013 |
7 | 4499413 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 2227714 | 7 |
0.018 | 2423498 | 9 |
0.019 | 1116544 | 7 |
0.020 | 3511497 | 16 |
0.021 | 1769124 | 11 |
Last trade - 11.25am 14/08/2024 (20 minute delay) ? |
Featured News
ADN (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online